Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis
Hepatology International · 2024
DOI: 10.1007/s12072-024-10700-7 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Hepatology International, 2024. Verfasst von Gui-Ji Lv und 12 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Hepatology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Liver Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: The risk of hepatocellular carcinoma (HCC) occurrence following antiviral therapy in patients with chronic hepatitis C (CHC) remains unclear. The current study aims to compare: (1) the HCC occurrence rate following sustained virological response (SVR) versus non-response (NR); (2) the HCC occurrence rate following direct-acting antiviral (DAA) therapy versus interferon (IFN)-based therapy, and (3) the HCC occurrence rate in SVR patients with or without cirrhosis. METHODS: A search was performed for articles published between January 2017 and July 2022. Studies were included if they assessed HCC occurrence rate in CHC patients following anti-HCV therapy. Random effects meta-analysis was used to synthesize the results from individual studies. RESULTS: A total of 23 studies including 29,395 patients (IFN-based = 6, DAA = 17; prospective = 10, retrospective = 13) were included in the review. HCC occurrence was significantly lower in CHC with SVR (1.54 per 100 person-years (py, 95% CI 1.52, 1.57) than those in non-responders (7.80 py, 95% CI 7.61, 7.99). Stratified by HCV treatment regimens, HCC occurrence following SVR was 1.17 per 100 py (95% CI 1.11, 1.22) and 1.60 per 100 py (95% CI 1.58, 1.63) in IFN- and DAA treatment-based studies. HCC occurrence was 0.85 per 100 py (95% CI 0.85, 0.86) in the non-cirrhosis population and rose to 2.47 per 100 py (95% CI 2.42, 2.52) in the cirrhosis population. Further meta-regression analysis showed that treatment types were not associated with a higher HCC occurrence rate, while cirrhosis status was an important factor of HCC occurrence rate. CONCLUSION: HCC occurrence was significantly lower in the SVR population than in the NR population. HCC risk following SVR occurred three times more frequently in patients with cirrhosis than patients without cirrhosis. However, we found no significant difference in HCC occurrence risk following SVR between DAA and IFN therapies. CLINICAL TRIAL NUMBER: CRD42023473033.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Hepatology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
- Peking University 302 Clinical Medical School, Beijing, 100039, China.
- Chinese PLA Medical School, Beijing, 100853, China.
- Hospital of North China Electric Power University, Beijing, 102206, China.
- JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, 9 Queen's Road Central, Central, Hong Kong SAR, China.
Zitieren
APA
Lv, G. J., Ji, D., Yu, L., Chen, H. Y., Chen, J., He, M., Wang, W. C., Wang, H. B., Tsang, C., Wang, J., Yu, M. L., Lau, G., & APASL Viral Elimination Task force (2024). Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Hepatology International. https://doi.org/10.1007/s12072-024-10700-7
Vancouver
Lv GJ, Ji D, Yu L, Chen HY, Chen J, He M, et al. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Hepatology International. 2024. doi:10.1007/s12072-024-10700-7
BibTeX
@article{Lv2024,
author = {Lv, Gui-Ji and Ji, Dong and Yu, Lingxiang and Chen, Hong-Yan and Chen, Jing and He, Mengwen and Wang, Wen-Chang and Wang, Hong-Bo and Tsang, Christopher and Wang, Jianjun and Yu, Ming-Lung and Lau, George and APASL Viral Elimination Task force, APASL Viral Elimination Task force},
title = {Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis},
journal = {Hepatology International},
year = {2024},
doi = {10.1007/s12072-024-10700-7}
}
EUVIMED